《Economic Information Daily 30th Special Report》Akeso (09926) is down 1.2%, trading at HK$105, with approximately 4.53 million shares traded, involving HK$471 million.

  Despite rising and record-high U.S. Treasury yields, northbound funds have shown clear activity before the National Day holiday, with net inflows of around HK$2.2 billion so far. Biotech stocks have notably risen against the market trend, currently receiving about HK$880 million in net active buying. Sub-sectors including innovative drugs, CXO, and AI-driven pharmaceuticals have attracted significant capital inflows, suggesting some northbound funds may intend to hold positions over the holiday. The biotechnology index is up 1.67%, or 268 points, at 16,318.

  Apart from Akeso, which retreated after yesterday's surge driven by news of its partner Summit receiving investment from AstraZeneca, most other biotech stocks performed well; Innovent Biologics (01801) rose 0.5% to HK$96.35; BeiGene (06160) gained 1.8% to HK$221.8; Genscript Biotech (01548) advanced 7.2% to HK$44.38; WuXi AppTec (02359) rose 1.2% to HK$210.2; CanSinoBIO (06185) surged 16.6% to HK$36.26; Insilico Medicine (03696) climbed 6% to HK$58.7; XtalPi (02228) gained 3.7% to HK$8.185.

  Currently, the Hang Seng Index stands at 24,406, down 116 points or 0.5%, with main board turnover exceeding HK$29.5 billion. The Hang Seng China Enterprises Index is at 8,139, down 39 points or 0.5%. The Hang Seng Tech Index is at 4,219, down 29 points or 0.7%.
 (hc)